Michael Gelband ExodusPoint Capital Management
Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$321M |
| 2 |
AABA
Altaba Inc
AABA
|
+$120M |
| 3 |
Amazon
AMZN
|
+$84M |
| 4 |
Dell
DELL
|
+$81.8M |
| 5 |
Meta Platforms (Facebook)
META
|
+$58M |
Top Sells
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.65% |
| 2 | Utilities | 16.59% |
| 3 | Communication Services | 9.1% |
| 4 | Consumer Discretionary | 6.67% |
| 5 | Industrials | 5.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
FMC
FMC
$1.38B
| $246K | 0.02% |
+3,836
| New | +$269K |
|
227
Eli Lilly
LLY
$1.12T
| $244K | 0.02% |
+2,106
| New | +$235K |
|
|
PRAH
228
DELISTED
PRA Health Sciences, Inc.
PRAH
| $244K | 0.02% |
+2,651
| New | +$268K |
|
229
Globus Medical
GMED
$11.7B
| $243K | 0.02% |
+5,605
| New | +$280K |
|
230
Novartis
NVS
$302B
| $243K | 0.02% |
+3,156
| New | +$246K |
|
231
RH
RH
$2.9B
| $243K | 0.02% |
+2,027
| New | +$244K |
|
232
Synchrony
SYF
$25.9B
| $242K | 0.02% |
+10,328
| New | +$279K |
|
233
Boston Beer
SAM
$1.91B
| $239K | 0.02% |
+992
| New | +$277K |
|
|
ROAN
234
DELISTED
Roan Resources, Inc.
ROAN
| $239K | 0.02% |
+28,500
| New | +$308K |
|
|
BDSI
235
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $238K | 0.02% |
+64,307
| New | +$226K |
|
236
American Financial Group
AFG
$11.9B
| $236K | 0.02% |
+2,607
| New | +$261K |
|
|
STR
237
DELISTED
Sitio Royalties
STR
| $234K | 0.02% |
+6,875
| New | +$245K |
|
238
HP
HPQ
$27.2B
| $231K | 0.02% |
+11,280
| New | +$263K |
|
239
Exelixis
EXEL
$13.4B
| $229K | 0.02% |
+11,643
| New | +$208K |
|
|
OSIR
240
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
| $228K | 0.02% |
+16,900
| New | +$189K |
|
241
Archer Daniels Midland
ADM
$38.7B
| $227K | 0.02% |
+5,548
| New | +$259K |
|
242
ENI
E
$81.5B
| $225K | 0.02% |
+7,134
| New | +$242K |
|
243
New Mountain Finance
NMFC
$714M
| $225K | 0.02% |
+17,900
| New | +$237K |
|
244
Wyndham Hotels & Resorts
WH
$5.54B
| $225K | 0.02% |
+4,968
| New | +$241K |
|
245
Gaming and Leisure Properties
GLPI
$12.7B
| $224K | 0.02% |
+6,923
| New | +$234K |
|
246
State Street Technology Select Sector SPDR ETF
XLK
$120B
| $223K | 0.02% |
+7,200
| New | +$244K |
|
247
Monolithic Power Systems
MPWR
$64.7B
| $222K | 0.02% |
+1,909
| New | +$228K |
|
248
Upbound Group
UPBD
$1.1B
| $222K | 0.02% |
+13,729
| New | +$199K |
|
249
Lennox International
LII
$13.9B
| $221K | 0.02% |
+1,008
| New | +$213K |
|
250
Parker-Hannifin
PH
$126B
| $221K | 0.02% |
+1,484
| New | +$240K |
|
Similar funds
Michael Gelband's Q4 2018 Portfolio in Review
Q4 2018 is the first quarter with a 13F filing on record for Michael Gelband, which disclosed 334 positions worth $1.42B. Its ten largest holdings account for 60% of the portfolio.
Its largest position is State Street SPDR S&P 500 ETF Trust: 1,189,219 shares worth $297M.
By sector, the portfolio is most concentrated in Technology at 17% of assets, followed by Utilities and Communication Services.
- Michael Gelband's largest Q4 2018 buy was State Street SPDR S&P 500 ETF Trust: 1,189,219 shares worth $297M.
- Michael Gelband's ten largest holdings make up 60% of its $1.42B portfolio in Q4 2018.
- Michael Gelband disclosed 334 positions in Q4 2018, its first 13F filing on record.
Based on ExodusPoint Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.